Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Cardiol Young ; 27(4): 797-800, 2017 May.
Artículo en Inglés | MEDLINE | ID: mdl-28077185

RESUMEN

Acromelic dysplasias are a group of skeletal dysplasias characterised by short-limbed short stature with other distinctive phenotypic features including small hands and feet and stiff joints. Geleophysic dysplasia is an acromelic dysplasia that is associated with characteristic facial features, progressive cardiac valvular thickening, and tracheal stenosis. Owing to overlapping clinical features with other types of short-limbed skeletal dysplasias, it is important to make a precise diagnosis as they have different cardiac morbidity and mortality. We present the cases of three patients with geleophysic dysplasia and progressive mitral valve disease to emphasise the natural history of this disorder and provide guidance regarding cardiac health supervision in these individuals.


Asunto(s)
Anomalías Múltiples/diagnóstico por imagen , Enfermedades del Desarrollo Óseo/complicaciones , Deformidades Congénitas de las Extremidades/complicaciones , Estenosis de la Válvula Mitral/diagnóstico por imagen , Enfermedades del Desarrollo Óseo/diagnóstico por imagen , Niño , Ecocardiografía , Femenino , Humanos , Recién Nacido , Deformidades Congénitas de las Extremidades/diagnóstico por imagen , Masculino , Válvula Mitral/diagnóstico por imagen , Válvula Mitral/fisiopatología , Embarazo , Ultrasonografía Prenatal
2.
ASAIO J ; 67(1): 91-95, 2021 01 01.
Artículo en Inglés | MEDLINE | ID: mdl-33346994

RESUMEN

Hemorrhagic and thrombotic complications are a significant source of morbidity and mortality for pediatric patients on extracorporeal membrane oxygenation (ECMO). Optimal anticoagulation therapies and monitoring strategies remain unknown. In 2013, our institution changed the anticoagulation monitoring protocol from activated clotting time (ACT) to antifactor Xa (anti-Xa) levels. We conducted a retrospective review of patients who received anticoagulation management directed by ACT results (n = 96) or anti-Xa levels (n = 72) between January 2010 and March 2016. Hemorrhagic complications occurred in 25% of the ACT group and 39% of the anti-Xa group (p = 0.054). Thrombotic complications were observed in 12.5% of the ACT group and 14% of the anti-Xa group (p = 0.8). There was a greater incidence of extracorporeal cardiopulmonary resuscitations (E-CPR; 36% vs. 15%; p = 0.005) in the anti-Xa group as compared with the ACT group. Secondary analysis showed no difference in transfusion requirements for red blood cells (ml/kg; p = 0.32) or platelets (ml/kg; p = 0.32). There was no difference in average heparin infusion rates (unit/kg/hr) per cannulation (p = 0.17) between the groups. Management of anticoagulation based on anti-Xa levels appears to be as effective as management based on ACT results.


Asunto(s)
Oxigenación por Membrana Extracorpórea/efectos adversos , Inhibidores del Factor Xa/sangre , Hemorragia/epidemiología , Trombosis/epidemiología , Anticoagulantes/uso terapéutico , Pruebas de Coagulación Sanguínea , Niño , Preescolar , Oxigenación por Membrana Extracorpórea/métodos , Femenino , Hemorragia/etiología , Heparina/uso terapéutico , Humanos , Masculino , Estudios Retrospectivos , Trombosis/etiología
3.
In. Hernández, María Cristina; Casavieja López, Mónica. Mediación y salud: perspectivas y prácticas. Montevideo, Colegio Médico del Uruguay, 2021. p.155-167.
Monografía en Español | LILACS, UY-BNMED, BNUY | ID: biblio-1378298

Asunto(s)
Humanos , Médicos , Negociación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA